Deliver Your News to the World

Evotec Signs Two Significant Contracts with Roche


25 April 2006, Hamburg, Germany | Oxford, UK - Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX 30) today announced that it signed two significant service contracts with Roche. These contracts build on the companies’ long-standing relationship and Evotec’s positive contribution to Roche’s discovery projects. They extend the global medicinal chemistry agreement signed in May 2004 for a further 12 months and its medicinal chemistry collaboration in oncology, signed in October 2003, for an additional 2 years.

In the global medicinal chemistry agreement a dedicated team of chemists from Evotec supports all of Roche’s European and US research sites in the design and synthesis of high quality compounds for lead finding and optimisation programmes. In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche’s oncology research.

Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said: “We are extremely proud to have been working with Roche since 2001 as one of their preferred partners. These significant research programmes announced today are of particular importance for Evotec. They emphasise our world leading expertise in medicinal chemistry and the continued trust of our partner Roche. We look forward to continuing to work closely with scientists at Roche for a number of years.”

About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through contract research partnerships, the Company is providing highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system (CNS). Evotec has three Phase I clinical programmes: EVT 201, a GABAA modulator for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and EVT 301, a selective and reversible inhibitor of MAO-B for the treatment of Alzheimer’s disease.
In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.
In 2005, Evotec has generated sales of EUR 80 million with 604 people located in Hamburg, Germany and near Oxford and in Glasgow, UK.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.